US Stock Insider Trading | Natera Discloses 21 Insider Transactions on February 4

K-LinePoet · 2026-02-20T14:00:48+00:00

On February 4, 2026, Natera disclosed insider trading activity, with Director Chapman Steven Leonard selling a total of 41,800 shares on February 2 and 3, involving over $9.6 million. The company focuses on genetic testing and disease management, committed to advancing personalized medicine.

K-LinePoet

2026-02-20 14:00:48

Abstract generation in progress

On February 4, 2026, Natera (NTRA) disclosed 21 insider trading transactions. Director Chapman Steven Leonard sold 41,800 shares on February 3, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 4, 2026	Director	Chapman Steven Leonard	February 2, 2026	Sell	9,197	232.41	2.1374 million
February 4, 2026	Director	Sheena Jonathan	February 3, 2026	Sell	435	230.77	100,400
February 4, 2026	Director	Chapman Steven Leonard	February 3, 2026	Sell	4,725	230.77	1.0904 million
February 4, 2026	Director	Chapman Steven Leonard	February 2, 2026	Sell	20,100	230.95	4.6372 million
February 4, 2026	Director	Chapman Steven Leonard	February 2, 2026	Sell	7,445	233.31	1.737 million
February 4, 2026	Director	Chapman Steven Leonard	February 2, 2026	Sell	100	234.00	23,400
February 4, 2026	Director	Chapman Steven Leonard	February 2, 2026	Sell	6,631	229.08	1.5191 million
February 4, 2026	Director	Chapman Steven Leonard	February 2, 2026	Sell	41,800	230.03	9.626 million
February 4, 2026	Executive	Brophy Michael Burkes	February 3, 2026	Sell	4,971	227.45	1.1306 million
February 4, 2026	Executive	Brophy Michael Burkes	February 3, 2026	Sell	700	225.25	157,700

[Company Profile]

Natera, Inc. was incorporated in Delaware in January 2007. The company is a diagnostics firm with proprietary molecular and bioinformatics technologies that are transforming disease management worldwide. Its cell-free DNA (cfDNA) technology combines innovative molecular analysis methods capable of reliably measuring numerous genomic regions from small to single-cell samples, along with statistical algorithms that incorporate data from the broader scientific community to identify genetic variations associated with a wide range of serious diseases with high precision and coverage. The company’s goal is to make personalized genetic testing and diagnostics a standard part of healthcare to protect health, enabling earlier and more targeted interventions to help achieve longer, healthier lives.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes